Published online July 1, 2008
PEDIATRICS Vol. 122 No. 1 July 2008, pp. e149-e155 (doi:10.1542/peds.2007-3398)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kheirandish-Gozal, L.
Right arrow Articles by Gozal, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kheirandish-Gozal, L.
Right arrow Articles by Gozal, D.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Intranasal Budesonide Treatment for Children With Mild Obstructive Sleep Apnea Syndrome

Leila Kheirandish-Gozal, MD and David Gozal, MD

Division of Pediatric Sleep Medicine, Department of Pediatrics, University of Louisville, Louisville, Kentucky

OBJECTIVES. Intranasal corticosteroids have been advanced as a nonsurgical therapeutic alternative for pediatric obstructive sleep apnea syndrome, particularly for patients with mild disease, and aims at reducing the size of hypertrophic adenotonsillar tissue.

METHODS. Of 71 possible candidates, 62 children with polysomnographically diagnosed mild obstructive sleep apnea syndrome were recruited onto a double-blind, randomized, crossover trial of intranasal budesonide (32 µg per nostril at bedtime) or placebo for 6 weeks followed by an additional 6-week treatment in the alternative treatment arm after allowing for a 2-week washout period. Polysomnographic assessment and radiographs for assessment of adenoid size were performed after completion of each phase.

RESULTS. There were significant improvements in both polysomnographic measures (sleep latency, slow-wave sleep, and rapid-eye-movement sleep), in the magnitude of respiratory disturbance (apnea/hypopnea index, nadir pulse oxygen saturation), and in adenoid size among the 48 children who completed the treatment phase compared with 32 children who received placebo in their initial arm, with normalization of sleep measures in 54.1% of the treated children. Furthermore, discontinuation of treatment for 8 weeks for 25 children revealed a sustained duration of the initial treatment effect.

CONCLUSIONS. A 6-week treatment with intranasal budesonide effectively reduced the severity of mild obstructive sleep apnea syndrome and the magnitude of the underlying adenoidal hypertrophy, and this effect persisted for at least 8 weeks after cessation of therapy. These findings justify the use of topical steroids as the initial therapeutic option in otherwise healthy children with mild obstructive sleep apnea.

Key Words: adenoid hypertrophy • upper airway resistance syndrome • budesonide • topical steroids • obstructive sleep apnea

Abbreviations: OSAS—obstructive sleep apnea syndrome • AHI—apnea/hypopnea index • T&A—surgical adenotonsillectomy • TST—total sleep time • PSG—polysomnographic • SpO2—pulse oxygen saturation • OAHI—obstructive apnea/hypopnea index • RAI—respiratory arousal index • N/P ratio—adenoidal nasopharyngeal ratio

Accepted Jan 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
A. G. Kaditis, E. Alexopoulos, K. Chaidas, G. Ntamagka, A. Karathanasi, I. Tsilioni, T. S. Kiropoulos, E. Zintzaras, and K. Gourgoulianis
Urine Concentrations of Cysteinyl Leukotrienes in Children With Obstructive Sleep-Disordered Breathing
Chest, June 1, 2009; 135(6): 1496 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Kheirandish-Gozal, L. D. Serpero, E. Dayyat, J. Kim, J. L. Goldman, A. Snow, R. Bhattacharjee, and D. Gozal
Corticosteroids suppress in vitro tonsillar proliferation in children with obstructive sleep apnoea
Eur. Respir. J., May 1, 2009; 33(5): 1077 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Dayyat, L. D. Serpero, L. Kheirandish-Gozal, J. L. Goldman, A. Snow, R. Bhattacharjee, and D. Gozal
Leukotriene Pathways and In Vitro Adenotonsillar Cell Proliferation in Children With Obstructive Sleep Apnea
Chest, May 1, 2009; 135(5): 1142 - 1149.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
Inhaled Steroids for Children with Obstructive Sleep Apnea
Journal Watch (General), July 29, 2008; 2008(729): 6 - 6.
[Full Text]